129 related articles for article (PubMed ID: 34323945)
21. Conjunctival extranodal marginal zone B-cell lymphoma with crystal-storing histiocytosis.
Mittal R; Damato B; Coupland SE
Acta Ophthalmol; 2015 Nov; 93(7):e602-3. PubMed ID: 25988528
[No Abstract] [Full Text] [Related]
22. Subcutaneous crystal-storing histiocytosis associated with lymphoplasmacytic lymphoma (immunocytoma).
Kaufmann O; Hansen A; Deicke P; Burmester GR; Dietel M
Pathol Res Pract; 1996 Nov; 192(11):1148-51. PubMed ID: 9122035
[TBL] [Abstract][Full Text] [Related]
23. Crystal storing histiocytosis: Unusual clinical presentations in two patients.
Tomsula J; Meis JM; Koy RD; Monheit J; Zieske A; Ro J; Ayala A
Ann Diagn Pathol; 2019 Jun; 40():13-17. PubMed ID: 30825790
[No Abstract] [Full Text] [Related]
24. Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma.
Merz M; Hielscher T; Schult D; Mai EK; Raab MS; Hillengass J; Seckinger A; Hose D; Granzow M; Jauch A; Goldschmidt H
Leukemia; 2020 Apr; 34(4):1192-1196. PubMed ID: 31712777
[No Abstract] [Full Text] [Related]
25. Crystal-storing histiocytosis as a cause of symptomatic cardiac mass.
Sailey CJ; Alexiev BA; Gammie JS; Pinell-Salles P; Stafford JL; Burke A
Arch Pathol Lab Med; 2009 Nov; 133(11):1861-4. PubMed ID: 19886724
[TBL] [Abstract][Full Text] [Related]
26. Crystal-storing histiocytosis complicating primary pulmonary marginal zone lymphoma of mucosa-associated lymphoid tissue.
Zhang C; Myers JL
Arch Pathol Lab Med; 2013 Sep; 137(9):1199-204. PubMed ID: 23991730
[TBL] [Abstract][Full Text] [Related]
27. Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
Gran C; Luong V; Bruchfeld JB; Liwing J; Afram G; Lund J; Usmani S; Alici E; Nahi H
Am J Hematol; 2021 Mar; 96(3):E63-E65. PubMed ID: 33264449
[No Abstract] [Full Text] [Related]
28. Renal crystal storing histiocytosis in a patient with multiple myeloma.
Farooq U; Bayerl MG; Abendroth CS; Verma N; Talamo G
Ann Hematol; 2009 Aug; 88(8):807-9. PubMed ID: 19119476
[No Abstract] [Full Text] [Related]
29. Crystal-Storing Histiocytosis: Report of a Rare Case Presenting With Pathological Fracture of Femur. Is There More to the Entity?
Uthamalingam P; Mehta S
Int J Surg Pathol; 2017 Aug; 25(5):458-461. PubMed ID: 28381142
[TBL] [Abstract][Full Text] [Related]
30. A challenging diagnosis: crystal-storing histiocytosis in plasma cell myeloma.
Lee JS; Im K; Park SN; Park HS; Kim JA; Choi Q; Kim SY; Cha CH; Oh HS; Kim IH; Lee DS
Am J Clin Pathol; 2015 Feb; 143(2):300-4. PubMed ID: 25596257
[TBL] [Abstract][Full Text] [Related]
31. Co-existence of Langerhans cell histiocytosis and reticulohistiocytosis with initial presentation of skull lesions: A case report.
Shen WC; Chang Liao NF; Lin TY; Wu PY
J Cutan Pathol; 2019 Jan; 46(1):62-66. PubMed ID: 30251332
[TBL] [Abstract][Full Text] [Related]
32. Aggressive systemic mastocytosis with Charcot-Leyden crystals-associated crystal storing histiocytosis in bone marrow.
Alayed KM; Alabdulaali MK; Alkhairy KS; Elnour S; Alhajjaj A
Pathology; 2010 Jan; 42(1):85-7. PubMed ID: 20025488
[No Abstract] [Full Text] [Related]
33. Plasma Cell Myeloma Presenting With Amyloid-Laden Crystal-Negative Histiocytosis.
Braunstein MJ; Petrova-Drus K; Rosenbaum CA; Jayabalan DS; Rossi AC; Salvatore S; Rech K; Pearse RN; Hassane DC; Postley J; Jhanwar YS; Geyer JT; Niesvizky R
Am J Clin Pathol; 2020 Nov; 154(6):767-775. PubMed ID: 32705137
[TBL] [Abstract][Full Text] [Related]
34. Differentiating Intralymphatic Histiocytosis, Intravascular Histiocytosis, and Subtypes of Reactive Angioendotheliomatosis: Review of Clinical and Histologic Features of All Cases Reported to Date.
Mazloom SE; Stallings A; Kyei A
Am J Dermatopathol; 2017 Jan; 39(1):33-39. PubMed ID: 28027079
[TBL] [Abstract][Full Text] [Related]
35. Crystal storing histiocytosis of the tongue as the initial presentation of multiple myeloma.
Khurram SA; McPhaden A; Hislop WS; Hunter KD
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Apr; 111(4):494-6. PubMed ID: 21420638
[TBL] [Abstract][Full Text] [Related]
36. Timing of treatment of smoldering myeloma: delay until progression.
Kumar SK
Blood Adv; 2018 Nov; 2(21):3050-3053. PubMed ID: 30425069
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow imprints of crystal-storing histiocytosis.
Kilic I; Picken MM; Velankar MM; Pambuccian SE
Diagn Cytopathol; 2020 Mar; 48(3):244-252. PubMed ID: 31833659
[No Abstract] [Full Text] [Related]
38. Risk Stratification and Treatment in Smoldering Multiple Myeloma.
Lussier T; Schoebe N; Mai S
Cells; 2021 Dec; 11(1):. PubMed ID: 35011692
[TBL] [Abstract][Full Text] [Related]
39. Crystal-storing histiocytosis in plasma cell myeloma.
Yang Y; Bekeris LG; Vogl DT; Bagg A
Am J Hematol; 2010 Jun; 85(6):444-5. PubMed ID: 19802881
[No Abstract] [Full Text] [Related]
40. Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma.
Francis ER; Chen F; Kidacki M; Miller R; Alkhasoneh M; Talamo G; Straub M; Klinefelter K; Kodali N; Zhu Y
Clin Chim Acta; 2018 Dec; 487():306-308. PubMed ID: 30315756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
